Inhibition of neovascularization to simultaneously ameliorate graft-vs-host disease and decrease tumor growth

Journal of the National Cancer Institute

Volumn 102, Issue 12, 2010, Pages 894-908

  Penack, Olaf ^a,b   Henke, Erik ^a   Suh, David ^a   King, Chris G ^a   Smith, Odette M ^a   Na, Il Kang ^a,b   Holland, Amanda M ^a,c   Ghosh, Arnab ^a   Lu, Sydney X ^a   Jenq, Robert R ^a   Liu, Chen ^e   Murphy, George F ^f   Lu, Theresa T ^d   May, Chad ^g   Scheinberg, David A ^a   Gao, Ding Cheng ^h   Mittal, Vivek ^h   Heller, Glenn ^a   Benezra, Robert ^a   Van Den Brink, Marcel R M ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c Autoimmunity and Inflammation Program   (United States)

^d HOSPITAL FOR SPECIAL SURGERY   (United States)

^e UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^f BRIGHAM AND WOMEN S HOSPITAL   (United States)

^g ELI LILLY AND COMPANY   (United States)

^h WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; CYTOKINE; E4G10 ANTIBODY; GREEN FLUORESCENT PROTEIN; UNCLASSIFIED DRUG; ANGIOGENESIS INHIBITOR; CADHERIN; LEUKOCYTE ANTIGEN; MONOCLONAL ANTIBODY; VASCULAR ENDOTHELIAL CADHERIN;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ALLOGENIC BONE MARROW TRANSPLANTATION; ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOLUMINESCENCE; BONE MARROW; CONTROLLED STUDY; DONOR; ENDOTHELIUM CELL; FEMALE; FLOW CYTOMETRY; GRAFT RECIPIENT; GRAFT VERSUS HOST REACTION; GROWTH INHIBITION; HISTOPATHOLOGY; HOST; IMMUNOASSAY; IMMUNOFLUORESCENCE MICROSCOPY; IMMUNOHISTOCHEMISTRY; INTESTINE; LIVER; LYMPHOMA; MOUSE; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PRIORITY JOURNAL; PROBABILITY; SURVIVAL; TREATMENT OUTCOME; TUMOR GROWTH; TUMOR VASCULARIZATION; ALLOTRANSPLANTATION; ANIMAL; BONE MARROW TRANSPLANTATION; C57BL MOUSE; FLUORESCENT ANTIBODY TECHNIQUE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOLOGY; NEOPLASM; VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD; BONE MARROW TRANSPLANTATION; CADHERINS; FEMALE; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; MICE; MICE, INBRED C57BL; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; TRANSPLANTATION, HOMOLOGOUS;

EID: 77953689269     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djq172     Document Type: Article

References (58)

1. Kerbel RS. Tumor angiogenesis. N Engl J Med. 2008;358(19): 2039-2049.
2. Ferrara N, Kerbel RS. Angiogenesis as a therapeutic target. Nature. 2005;438(7070):967-974.
3. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science. 2005;307(5706):58-62.
4. Ellis LM, Hicklin DJ. VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat Rev Cancer. 2008;8(8):579-591.
5. Halin C, Fahrngruber H, Meingassner JG, et al. Inhibition of chronic and acute skin infammation by treatment with a vascular endothelial growth factor receptor tyrosine kinase inhibitor. Am J Pathol. 2008;173(1): 265-277.
6. Danese S, Sans M, Spencer DM, et al. Angiogenesis blockade as a new therapeutic approach to experimental colitis. Gut. 2007;56(6):855-862.
7. Firestein GS. Starving the synovium: angiogenesis and infammation in rheumatoid arthritis. J Clin Invest. 1999;103(1):3-4.
8. Stoll BR, Migliorini C, Kadambi A, Munn LL, Jain RK. A mathematical model of the contribution of endothelial progenitor cells to angiogenesis in tumors: implications for antiangiogenic therapy. Blood. 2003;102(7): 2555-2561.
9. Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol. 2005;23(5): 1011-1027.
10. Gao D, Nolan DJ, Mellick AS, Bambino K, McDonnell K, Mittal V. Endothelial progenitor cells control the angiogenic switch in mouse lung metastasis. Science. 2008;319(5860):195-198.
11. Lyden D, Hattori K, Dias S, et al. Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angio-genesis and growth. Nat Med. 2001;7(11):1194-1201.
12. Nolan DJ, Ciarrocchi A, Mellick AS, et al. Bone marrow-derived endothe-lial progenitor cells are a major determinant of nascent tumor neovascu-larization. Genes Dev. 2007;21(12):1546-1558.
13. Shaked Y, Ciarrocchi A, Franco M, et al. Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors. Science. 2006;313(5794):1785-1787.
14. Singh Jaggi J, Henke E, Seshan SV, et al. Selective alpha-particle mediated depletion of tumor vasculature with vascular normalization. PLoS ONE. 2007;2(3):e267.
15. Ciarrocchi A, Jankovic V, Shaked Y, et al. Id1 restrains p21 expression to control endothelial progenitor cell formation. PLoS ONE. 2007;2(12):e1338.
16. Bailey AS, Jiang S, Afentoulis M, et al. Transplanted adult hematopoietic stems cells differentiate into functional endothelial cells. Blood. 2004; 103(1):13-19.
17. Bertolini F, Mancuso P, Kerbel RS. Circulating endothelial progenitor cells. N Engl J Med. 2005;353(24):2613-2616author reply 2613-2616.
18. Alpdogan O, Schmaltz C, Muriglan SJ, et al. Administration of interleu-kin-7 after allogeneic bone marrow transplantation improves immune reconstitution without aggravating graft-versus-host disease. Blood. 2001; 98(7):2256-2265.
19. Penack O, Smith OM, Cunningham-Bussel A, et al. NOD2 regulates he-matopoietic cell function during graft-versus-host disease. J Exp Med. 2009;206(10):2101-2110.
20. Zakrzewski JL, Kochman AA, Lu SX, et al. Adoptive transfer of T-cell precursors enhances T-cell reconstitution after allogeneic hematopoietic stem cell transplantation. Nat Med. 2006;12(9):1039-1047.
21. Asahara T, Murohara T, Sullivan A, et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science. 1997;275(5302):964-967.
22. Cooke KR, Kobzik L, Martin TR, et al. An experimental model of idio-pathic pneumonia syndrome after bone marrow transplantation: I. The roles of minor H antigens and endotoxin. Blood. 1996;88(8):3230-3239.
23. Hill GR, Crawford JM, Cooke KR, Brinson YS, Pan L, Ferrara JL. Total body irradiation and acute graft-versus-host disease: the role of gastrointestinal damage and infammatory cytokines. Blood. 1997;90(8):3204-3213.
24. Ferrara J, Guillen FJ, Sleckman B, Burakoff SJ, Murphy GF. Cutaneous acute graft-versus-host disease to minor histocompatibility antigens in a murine model: histologic analysis and correlation to clinical disease. J Invest Dermatol. 1986;86(4):371-375. (Pubitemid 16050011)
25. Zakrzewski JL, Suh D, Markley JC, et al. Tumor immunotherapy across MHC barriers using allogeneic T-cell precursors. Nat Biotechnol. 2008; 26(4):453-461.
26. Terwey TH, Kim TD, Kochman AA, et al. CCR2 is required for CD8-induced graft-versus-host disease. Blood. 2005;106(9):3322-3330.
27. Vestweber D. VE-cadherin: the major endothelial adhesion molecule controlling cellular junctions and blood vessel formation. Arterioscler Thromb Vasc Biol. 2008;28(2):223-232.
28. Dejana E. Endothelial cell-cell junctions: happy together. Nat Rev Mol Cell Biol. 2004;5(4):261-270.
29. May C, Doody JF, Abdullah R, et al. Identifcation of a transiently exposed VE-cadherin epitope that allows for specifc targeting of an antibody to the tumor neovasculature. Blood. 2005;105(11):4337-4344.
30. Hirst DG, Denekamp J, Hobson B. Proliferation studies of the endothelial and smooth muscle cells of the mouse mesentery after irradiation. Cell Tissue Kinet. 1980;13(1):91-104.
31. Kim KW, Moretti L, Lu B. M867, a novel selective inhibitor of caspase-3 enhances cell death and extends tumor growth delay in irradiated lung cancer models. PLoS ONE. 2008;3(5):e2275.
32. Kunnumakkara AB, Diagaradjane P, Guha S, et al. Curcumin sensitizes human colorectal cancer xenografts in nude mice to gamma-radiation by targeting nuclear factor-kappaB-regulated gene products. Clin Cancer Res. 2008;14(7):2128-2136.
33. Lovey J, Bereczky B, Gilly R, et al. Recombinant human erythropoietin alpha improves the effcacy of radiotherapy of a human tumor xenograft, affecting tumor cells and microvessels. Strahlenther Onkol. 2008;184(1): 1-7.
34. Runkel S, Hunter N, Milas L. An intradermal assay for quantifcation and kinetics studies of tumor angiogenesis in mice. Radiat Res. 1991;126(2): 237-243.
35. Sholley MM, Ferguson GP, Seibel HR, Montour JL, Wilson JD. Mechanisms of neovascularization. Vascular sprouting can occur without proliferation of endothelial cells. Lab Invest. 1984;51(6):624-634.
36. Sinzinger H, Wicke L, Willvonseder R, et al. [Morphological and cytoki-netic studies of the arterial wall following X-ray irradiation. I. Results with 3000 rad. focal irradiation dose in rabbits]. Acta Morphol Neerl Scand. 1976;14(3):201-214.
37. Timke C, Zieher H, Roth A, et al. Combination of vascular endothelial growth factor receptor/platelet-derived growth factor receptor inhibition markedly improves radiation tumor therapy. Clin Cancer Res. 2008; 14(7):2210-2219.
38. Huber PE, Bischof M, Jenne J, et al. Trimodal cancer treatment: benef-cial effects of combined antiangiogenesis, radiation, and chemotherapy. Cancer Res. 2005;65(9):3643-3655.
39. Manegold PC, Paringer C, Kulka U, et al. Antiangiogenic therapy with mammalian target of rapamycin inhibitor RAD001 (Everolimus) increases radiosensitivity in solid cancer. Clin Cancer Res. 2008;14(3):892-900.
40. Spalding AC, Zeitlin BD, Wilder-Romans K, et al. Enzastaurin, an inhibitor of PKCbeta, enhances antiangiogenic effects and cytotoxicity of radiation against endothelial cells. Transl Oncol. 2008;1(4):195-201.
41. Samlowski WE, Johnson HM, Hammond EH, Robertson BA, Daynes RA. Marrow ablative doses of gamma-irradiation and protracted changes in peripheral lymph node microvasculature of murine and human bone marrow transplant recipients. Lab Invest. 1987;56(1):85-95.
42. Camplejohn RS, Penhaligon M. The tumour bed effect: a cell kinetic and histological investigation of tumours growing in irradiated mouse skin. Br J Radiol. 1985;58(689):443-451.
43. Penhaligon M, Courtenay VD, Camplejohn RS. Tumour bed effect: hyp-oxic fraction of tumours growing in preirradiated beds. Int J Radiat Biol Relat Stud Phys Chem Med. 1987;52(4):635-641.
44. Zips D, Eicheler W, Bruchner K, et al. Impact of the tumour bed effect on microenvironment, radiobiological hypoxia and the outcome of fractionated radiotherapy of human FaDu squamous-cell carcinoma growing in the nude mouse. Int J Radiat Biol. 2001;77(12):1185-1193.
45. Ahn GO, Brown JM. Matrix metalloproteinase-9 is required for tumor vasculogenesis but not for angiogenesis: role of bone marrow-derived myelomonocytic cells. Cancer Cell. 2008;13(3):193-205.
46. Lee JI, Itasaka S, Kim JT, Nam DH. Antiangiogenic agent, thalidomide increases the antitumor effect of single high dose irradiation (gamma knife radiosurgery) in the rat orthotopic glioma model. Oncol Rep. 2006; 15(5):1163-1168.
47. Duda DG, Cohen KS, Kozin SV, et al. Evidence for incorporation of bone marrow-derived endothelial cells into perfused blood vessels in tumors. Blood. 2006;107(7):2774-2776.
48. Larrivee B, Niessen K, Pollet I, et al. Minimal contribution of marrow-derived endothelial precursors to tumor vasculature. J Immunol. 2005;175(5):2890-2899.
49. Spring H, Schuler T, Arnold B, Hammerling GJ, Ganss R. Chemokines direct endothelial progenitors into tumor neovessels. Proc Natl Acad Sci USA. 2005;102(50):18111-18116.
50. Asosingh K, Swaidani S, Aronica M, Erzurum SC. Th1-and Th2-dependent endothelial progenitor cell recruitment and angiogenic switch in asthma. J Immunol. 2007;178(10):6482-6494.
51. Silverman MD, Haas CS, Rad AM, Arbab AS, Koch AE. The role of vascular cell adhesion molecule 1/very late activation antigen 4 in endo-thelial progenitor cell recruitment to rheumatoid arthritis synovium. Arthritis Rheum. 2007;56(6):1817-1826.
52. Liao F, Doody JF, Overholser J, et al. Selective targeting of angiogenic tumor vasculature by vascular endothelial-cadherin antibody inhibits tumor growth without affecting vascular permeability. Cancer Res. 2002;62(9):2567- 2575. (Pubitemid 34462736)
53. Min CK, Kim SY, Lee MJ, et al. Vascular endothelial growth factor (VEGF) is associated with reduced severity of acute graft-versus-host disease and nonrelapse mortality after allogeneic stem cell transplantation. Bone Marrow Transplant. 2006;38(2):149-156.
54. Kim DH, Lee NY, Lee MH, Sohn SK. Vascular endothelial growth factor gene polymorphisms may predict the risk of acute graft-versus-host disease following allogeneic transplantation: preventive effect of vascular endothelial growth factor gene on acute graft-versus-host disease. Biol Blood Marrow Transplant. 2008;14(12):1408-1416.
55. Kumpers P, Koenecke C, Hecker H, et al. Angiopoietin-2 predicts disease-free survival after allogeneic stem cell transplantation in patients with high-risk myeloid malignancies. Blood. 2008;112(5):2139-2148.
56. Lee CY, Tien HF, Hu CY, Chou WC, Lin LI. Marrow angiogenesis-associated factors as prognostic biomarkers in patients with acute myelog-enous leukaemia. Br J Cancer. 2007;97(7):877-882.
57. Schliemann C, Bieker R, Thoennissen N, et al. Circulating angiopoietin-2 is a strong prognostic factor in acute myeloid leukemia. Leukemia. 2007; 21(9):1901-1906.
58. Manzur M, Hamzah J, Ganss R. Modulation of the "blood-tumor" barrier improves immunotherapy. Cell Cycle. 2008;7(16):2452-2455.